Last updated on November 2019

A Study to Evaluate the Safety and Efficacy of CRN00808 for the Treatment of Acromegaly


Brief description of study

A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 (an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.

Clinical Study Identifier: NCT03792555

Find a site near you

Start Over